Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 9/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 9/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CFB | P00751 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12156688 | 1.00 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1HRH3 | |
| SCHEMBL12891026 | 1.00 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1HRH3 | |
| SCHEMBL13500529 | 0.94 | CFB (0.38) | POLBL3MBTL1SPHK2SPHK1CFB | |
| SCHEMBL13212589 | 0.94 | CFB (0.38) | POLBL3MBTL1SPHK2SPHK1CFB | |
| SCHEMBL13212595 | 0.94 | CFB (0.38) | POLBL3MBTL1SPHK2SPHK1CFB | |
| SCHEMBL16939340 | 0.88 | L3MBTL1 (0.34) | POLBL3MBTL1SPHK2SPHK1 | |
| SCHEMBL16939209 | 0.88 | L3MBTL1 (0.34) | POLBL3MBTL1SPHK2SPHK1 | |
| SCHEMBL21451253 | 0.85 | L3MBTL1 (0.42) | POLBL3MBTL1ALDH1A1 | |
| SCHEMBL6428879 | 0.85 | POLB (0.40) | POLBL3MBTL1SPHK2SPHK1PARP1 | |
| SCHEMBL6948011 | 0.85 | POLB (0.40) | POLBL3MBTL1SPHK2SPHK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571426-B2 | Compositions for preventing or treating lupus | CHONG KUN DANG PHARMACEUTICAL CORP. | 2023-02-07 | — | — | US | disclosed |
| US-20210161905-A1 | Compositions for Preventing or Treating Dry Eye | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2021-06-03 | — | — | US | disclosed |
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-03-18 | — | — | US | disclosed |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-11-26 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-9359358-B2 | Cyclohexyl azetidine derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | INCYTE CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | POLB 3623/4885L3MBTL1 1242/4885SPHK2 3427/4885 |
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | UACA, PDE6C, PDE6H | POLB 4676/4885L3MBTL1 4884/4885SPHK2 237/4885 |
| US-11571426-B2 | Compositions for preventing or treating lupus | SSB, TLR9, TLR5 | POLB 3661/4885L3MBTL1 4115/4885SPHK2 128/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | POLB 3711/4885L3MBTL1 2568/4885SPHK2 1107/4885 |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | POLB 829/4885L3MBTL1 4390/4885SPHK2 2684/4885 |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | POLB 829/4885L3MBTL1 4390/4885SPHK2 2684/4885 |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | SSB, TLR9, TLR5 | POLB 3661/4885L3MBTL1 4115/4885SPHK2 128/4885 |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | POLB 3310/4885L3MBTL1 24/4885SPHK2 3516/4885 |
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | JAK1, JAK2, JAK3 | POLB 3512/4885L3MBTL1 4496/4885SPHK2 748/4885 |
| US-20210161905-A1 | Compositions for Preventing or Treating Dry Eye | PDE6H, PDE6C, PDE6D | POLB 4751/4885L3MBTL1 4876/4885SPHK2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.